Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb27564 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F | EXPERIMENTAL | - |
| Single Ascending Dose - Placebo Subcutaneous injection of placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| XmAb27564 | DRUG | Single ascending dose of XmAb27564 |
| Placebo | DRUG | Single dose of placebo |
Inclusion Criteria: * Total body weight 50.0 to 100.0 kg and body mass index (BMI) 19.0 to 35.0 kg/m2 * In good general health with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease. * A ...
XmAb27564 is an investigational small molecule developed by Xencor, Inc. that targets ENPP3. It has been studied in a Phase 1 trial in healthy adult volunteers in the United States. Its clinical development remains at the early Phase 1 stage, and it is not an approved medicine.
XmAb27564 targets ENPP3, an enzyme that is the molecular target of this small molecule. By binding ENPP3, the compound is designed to act on that specific target. ENPP3 is the only mechanism-related detail disclosed for this asset, and the specific disease indications being pursued have not been publicly disclosed.
XmAb27564 is developed by Xencor, Inc., a clinical-stage biopharmaceutical company whose common stock trades on Nasdaq under the ticker symbol XNCR. Xencor is the sponsor of the clinical program for XmAb27564, which is built on the company's XmAb engineering platform.
XmAb27564 is in Phase 1 clinical development. Its only recorded trial is a completed Phase 1 study in healthy volunteers. The asset is investigational and has not been approved by the FDA for any indication, so it is not available as a marketed therapy.
XmAb27564 has been evaluated in one clinical trial, NCT04857866, titled "Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers." This completed Phase 1 study enrolled 48 healthy adult participants aged 21 and older in the United States and was randomized, double-blind, and placebo-controlled.